Tina Gullotta Net Worth

The estimated Net Worth of Tina Gullotta is at least $109 mil dollars as of 29 May 2020. Ms. Gullotta owns over 6,000 units of Sunesis Pharmaceuticals Inc stock worth over $109,060 and over the last 4 years she sold SNSS stock worth over $0. In addition, she makes $0 as Principal Accounting Officer e Vice President - Finance at Sunesis Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Gullotta SNSS stock SEC Form 4 insiders trading

Tina has made over 1 trades of the Sunesis Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 6,000 units of SNSS stock worth $1,980 on 29 May 2020.

The largest trade she's ever made was buying 6,000 units of Sunesis Pharmaceuticals Inc stock on 29 May 2020 worth over $1,980. On average, Tina trades about 6,000 units every 0 days since 2020. As of 29 May 2020 she still owns at least 20,500 units of Sunesis Pharmaceuticals Inc stock.

You can see the complete history of Ms. Gullotta stock trades at the bottom of the page.

Tina Gullotta biography

Tina Gullotta serves as Principal Accounting Officer, Vice President - Finance of the Company. Ms. Gullotta joined the Company in August 2018 with extensive experience in accounting, finance, and investor relations in the biotech industry. Prior to joining the Company, Ms. Gullotta was the Corporate Controller and held various other management positions at Atara Biotherapeutics, Inc. a public immunotherapy company, from February 2014 to January 2018. Prior to joining Atara Biotherapeutics, Inc. Ms. Gullotta held financial management positions in various industries including retail and telecommunications, and began her career in the business assurance practice with PricewaterhouseCoopers LLP. Ms. Gullotta received a B.S.C. in Accounting from Santa Clara University.

How old is Tina Gullotta?

Tina Gullotta is 46, she's been the Principal Accounting Officer e Vice President - Finance of Sunesis Pharmaceuticals Inc since 2020. There are 7 older and 1 younger executives at Sunesis Pharmaceuticals Inc. The oldest executive at Sunesis Pharmaceuticals Inc is H. Ward Wolff, 71, who is the Director.

What's Tina Gullotta's mailing address?

Tina's mailing address filed with the SEC is SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, STE. 400, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Sunesis Pharmaceuticals Inc

Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over $89,557,714 worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth $84,730,221 . The most active insiders traders include Forest Baskett, Scott D Sandell, ePeter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of $14,060,191. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth $1,980.

What does Sunesis Pharmaceuticals Inc do?

Complete history of Ms. Gullotta stock trades at Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Inc executives and stock owners

Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Adam Craig,
  Executive Vice President - Development, Chief Medical Officer
• Stephen Ketchum,
  Director
• David Stump,
  Independent Director
• Homer Pearce,
  Independent Director
• Nicole Onetto,
  Independent Director
• Matthew Fust,
  Independent Director
• Steve Carchedi,
  Independent Director
• H. Ward Wolff,
  Director
• Tina Gullotta,
  Principal Accounting Officer, Vice President - Finance
• Dayton Misfeldt,
  Chief Executive Officer, Principal Financial Officer, Secretary, Director
• James Young,
  Non-Executive Independent Chairman of the Board
• Eric Bjerkholt,
  EVP, CFO & Corp. Secretary
• Geoffrey M. Parker,
  Director
• Steven B Ketchum,
  Director
• Daniel N Jr Swisher,
  President and CEO
• Oncology Impact Management ...,
  
• William P. Quinn,
  See Remarks
• Judith A. Fox,
  See Remarks
• Patrick J Kerins,
  10% owner
• Ryan D Drant,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Equity Opportunities Fund, ...,
  
• City Capital Llc Bay City C...,
  
• Scott D Sandell,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Helen Susan Kim,
  Director
• Joseph I De Pinto,
  EVP, CCO
• Biopharma Partners Iii Lpal...,
  
• Equity Opportunities Fund, ...,
  
• Robert Scott Mc Dowell,
  Vice President, Research
• Edward Hurwitz,
  Director
• Dominique Semon,
  10% owner
• Biopharma Partners Iii Lpal...,
  
• Iii Eugene A Trainor,
  10% owner
• Charles M Linehan,
  10% owner
• Equity Opportunities Fund, ...,
  
• Pincus Equity Partners Lpwa...,
  
• Valerie L Pierce,
  Sr. VP, GC & Corp. Secretary
• Anthony B Evnin,
  Director
• Steven D Goldby,
  Director
• James A Wells,
  Director
• Stephen P A Fodor,
  Director
• Idec Incbiogen Idec Ma Inc ...,
  
• Pincus Equity Partners Lpwa...,
  
• Daniel C Md Adelman,
  Senior VP,Drug Discovery & Dev
• Ixmayfield Ix Management Ll...,
  
• Jonathan S Leff,
  Director
• Daryl B Winter,
  SVP,Gen Counsel/Corp Secretary
• Capital Iv, Lp Aisling Capi...,